Literature DB >> 19074869

Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Vitaly Balan1, Pratima Nangia-Makker, Ann G Schwartz, Young Suk Jung, Larry Tait, Victor Hogan, Tirza Raz, Yi Wang, Zeng Quan Yang, Gen Sheng Wu, Yongjun Guo, Huixiang Li, Judith Abrams, Fergus J Couch, Wilma L Lingle, Ricardo V Lloyd, Stephen P Ethier, Michael A Tainsky, Avraham Raz.   

Abstract

For reasons largely unknown, Caucasian women are at a significantly higher risk of developing breast cancer than Asian women. Over a decade ago, mutations in BRCA1/2 were identified as genetic risk factors; however, the discovery of additional breast cancer genes and genes contributing to racial disparities are lacking. We report a functional germline mutation (polymorphism) in the galectin-3 gene at position 191 (rs4644) substituting proline with histidine (P64H), which results in susceptibility to matrix metalloproteinase cleavage and acquisition of resistance to drug-induced apoptosis. This substitution correlates with incidence of breast cancer and racial disparity. Genotype analysis of 338 Caucasian (194 disease free and 144 breast cancer patients) and 140 Asian (79 disease free and 61 breast cancer patients) women showed that the allele homozygous for H64 exists in disease free Caucasian and Asian women at a frequency of 12% and 5%, respectively, versus 37% and 82% in breast cancer patients. The data indicate that H/H allele is associated with increased breast cancer risk in both races. The data implicate galectin-3 H(64) in breast cancer and explain, in part, the noted racial disparity, thus providing a novel target for diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074869      PMCID: PMC2882172          DOI: 10.1158/0008-5472.CAN-08-3224

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis.

Authors:  P Nangia-Makker; Y Honjo; R Sarvis; S Akahani; V Hogan; K J Pienta; A Raz
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest.

Authors:  Tadashi Yoshii; Tomoharu Fukumori; Yuichiro Honjo; Hidenori Inohara; Hyeong-Reh Choi Kim; Avraham Raz
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

3.  Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions.

Authors:  Malathy P V Shekhar; Pratima Nangia-Makker; Larry Tait; Fred Miller; Avraham Raz
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma.

Authors:  M M Lotz; C W Andrews; C A Korzelius; E C Lee; G D Steele; A Clarke; A M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

5.  Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis.

Authors:  R D Zhang; I J Fidler; J E Price
Journal:  Invasion Metastasis       Date:  1991

6.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9.

Authors:  J Ochieng; R Fridman; P Nangia-Makker; D E Kleiner; L A Liotta; W G Stetler-Stevenson; A Raz
Journal:  Biochemistry       Date:  1994-11-29       Impact factor: 3.162

7.  Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways.

Authors:  Tomoharu Fukumori; Yukinori Takenaka; Natsuo Oka; Tadashi Yoshii; Victor Hogan; Hidenori Inohara; Hiro-Omi Kanayama; Hyeong-Reh Choi Kim; Avraham Raz
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

8.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

9.  Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.

Authors:  Pratima Nangia-Makker; Tirza Raz; Larry Tait; Victor Hogan; Rafael Fridman; Avraham Raz
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

10.  A genome wide linkage search for breast cancer susceptibility genes.

Authors:  Paula Smith; Lesley McGuffog; Douglas F Easton; Graham J Mann; Gulietta M Pupo; Beth Newman; Georgia Chenevix-Trench; Csilla Szabo; Melissa Southey; Hélène Renard; Fabrice Odefrey; Henry Lynch; Dominique Stoppa-Lyonnet; Fergus Couch; John L Hopper; Graham G Giles; Margaret R E McCredie; Saundra Buys; Irene Andrulis; Ruby Senie; David E Goldgar; Rogier Oldenburg; Karin Kroeze-Jansema; Jaennelle Kraan; Hanne Meijers-Heijboer; Jan G M Klijn; Christi van Asperen; Inge van Leeuwen; Hans F A Vasen; Cees J Cornelisse; Peter Devilee; Linda Baskcomb; Sheila Seal; Rita Barfoot; Jon Mangion; Anita Hall; Sarah Edkins; Elizabeth Rapley; Richard Wooster; Jenny Chang-Claude; Diana Eccles; D Gareth Evans; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Nazneen Rahman; Michael R Stratton
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

View more
  23 in total

Review 1.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

2.  Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer.

Authors:  Seok-Jun Kim; Ji-Young Shin; Teak-Chin Cheong; Il-Ju Choi; Yeon Su Lee; Seok Hee Park; Kyung-Hee Chun
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

Review 3.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

4.  Unraveling functional significance of natural variations of a human galectin by glycodendrimersomes with programmable glycan surface.

Authors:  Shaodong Zhang; Ralph-Olivier Moussodia; Sabine Vértesy; Sabine André; Michael L Klein; Hans-Joachim Gabius; Virgil Percec
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

5.  Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma.

Authors:  Sarika Saraswati; Ashley S Block; Mari K Davidson; Roger G Rank; Maha Mahadevan; Alan B Diekman
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

6.  Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.

Authors:  Fenglei Wu; Nan Hu; Yu Li; Baoxiang Bian; Guanghui Xu; Yitong Zheng
Journal:  Cell Oncol (Dordr)       Date:  2012-04-03       Impact factor: 6.730

Review 7.  Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.

Authors:  Kosei Nakajima; Dong Hyo Kho; Takashi Yanagawa; Melissa Zimel; Elisabeth Heath; Victor Hogan; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

8.  A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells.

Authors:  Nachman Mazurek; James C Byrd; Yunjie Sun; Suguru Ueno; Robert S Bresalier
Journal:  Cancer       Date:  2011-03-28       Impact factor: 6.860

Review 9.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

10.  Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

Authors:  Kyoko Yorozuya; Toru Takeuchi; Miwa Yoshida; Yukako Mouri; Junko Kousaka; Kimihito Fujii; Shogo Nakano; Takashi Fukutomi; Kazuo Hara; Shu Ichihara; Yingsong Lin; Shogo Kikuchi
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.